Dichlorohexylcarbodiimide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Dichlorohexylcarbodiimide
• 英文别名: n,n'-Dichlorohexylcarbodiimide
• 化学式: C₇H₁₂Cl₂N₂
• 分子量: 195.092
• InChiKey: RKEXIZXLDDCPRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  36.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  烟酸 、 Dichlorohexylcarbodiimide 、 酪胺盐酸盐 以 吡啶 为溶剂， 以6.25 g (86%)的产率得到N-[2-(4-hydroxyphenyl)ethyl]-3-pyridinecarboxamide
  参考文献：
  名称：

  Brain-specific drug delivery

  摘要：

  中央作用药物种类通过将治疗有效量的目标药物种类[D]系结到一种降低的、穿透血脑屏障的脂质形式[D-DHC]的二氢吡啶.反应.吡啶盐型氧化还原载体中，通过向需要此类治疗的患者施用，将药物直接传递到大脑。体内二氢吡啶载体基团的氧化形成离子型吡啶盐型药物/载体实体[D-QC].sup.+可以防止其从大脑中被清除，同时加速从全身循环中的清除，随后对季铵载体/药物种类的裂解导致药物[D]在大脑中的持续释放，以及载体基团[QC].sup.+的容易清除。

  公开号：

  US04479932A1

文献信息

• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DES TYROSINE KINASES
  申请人：MERCK & CO INC

  公开号：WO2005009957A1

  公开（公告）日：2005-02-03

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a substituted pyrrole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

  本发明涉及能够抑制、调节和/或调控受体型和非受体型酪氨酸激酶信号传导的化合物。本发明的化合物具有包含取代吡咯基团的核心结构。本发明还涉及这些化合物的药用盐、水合物和立体异构体。
• Nerve cell protective agents
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：US06040331A1

  公开（公告）日：2000-03-21

  The invention provides novel benzindole derivatives, processes for producing them, as well as a neuroprotective agent, an agent to prevent or treat diseases involving the degeneration, retraction or death of neurons, and an analgesic, each containing the benzindole derivatives as an active ingredient. ##STR1##

  这项发明提供了新颖的苯并吲唑衍生物，以及生产它们的方法，还包括一种神经保护剂、一种预防或治疗涉及神经元退化、萎缩或死亡的疾病的药物，以及一种镇痛剂，每种药物均含有苯并吲唑衍生物作为活性成分。
• Aminobutyric acid derivatives
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US06420427B1

  公开（公告）日：2002-07-16

  An aminobutyric acid derivative of the formula (I): (wherein all symbols are as defined in the specification) and salt thereof. salt thereof. The compounds of the formula (I) possess an inhibitory activity on matrix metalloproteinase and are useful for prevention and/or treatment of diseases, for example, rheumatoid diseases, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune disease (e.g. Crohn's disease, Sjogren's syndrome), disease caused by vascular emigration or infiltration of leukocytes, arterialization, multiple sclerosis, aorta aneurysm, endometriosis.

  一种公式（I）的氨基丁酸衍生物及其盐。其中所有符号均如规范中定义。公式（I）的化合物具有对基质金属蛋白酶的抑制活性，可用于预防和/或治疗疾病，例如风湿性疾病、关节炎、异常骨吸收、骨质疏松症、牙周炎、间质性肾炎、动脉硬化、肺气肿、肝硬化、角膜损伤、肿瘤细胞的转移、侵袭或生长、自身免疫性疾病（例如克罗恩病、干燥综合征）、由血管外移或白细胞浸润引起的疾病、动脉化、多发性硬化症、主动脉瘤、子宫内膜异位症。
• Podophyllotoxin derivatives as antitumor agents
  申请人：Kamal Ahmed

  公开号：US20070066837A1

  公开（公告）日：2007-03-22

  This invention relates to podophyllotoxin derivatives, more particularly to 4β-amino and 4β-amido derivatives of podophyllotoxin and 4′-O-demethylepipodophyllotoxin, which are useful for the treatment of tumors. Processes for the preparation of the compounds disclosed herein, pharmaceutical compositions containing these compounds, and methods for treating tumors are provided. The invention further relates to stereoselective compounds of podophyllotoxin and 4′-O-demethylepipodophyllotoxin derivatives.

  本发明涉及足叶草毒素衍生物，更具体地涉及4β-氨基和4β-酰胺衍生物以及4'-O-去甲基表儿茶素，这些衍生物对肿瘤的治疗有用。本发明提供了制备所述化合物的方法，含有这些化合物的制药组合物以及治疗肿瘤的方法。本发明还涉及足叶草毒素和4'-O-去甲基表儿茶素衍生物的立体选择性化合物。
• [EN] 3'-N-SUBSTITUTED-3-O-SUBSTITUTED ERYTHRONOLIDE A DERIVATIVES<br/>[FR] DERIVES D'ERYTHRONOLIDE A 3'-N-SUBSTITUES-3-O-SUBSTITUES
  申请人：RANBAXY LAB LTD

  公开号：WO2005030786A1

  公开（公告）日：2005-04-07

  This invention generally relates to macrolides, more particularly, the invention relates to 3-N-substituted-3-O-substituted erythronolide A derivatives, which are antibacterial agents effective against gram positive or gram negative bacteria and atypical pathogens. The compounds of this invention are more particularly effective against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating bacterial infection.

  本发明一般涉及大环内酯类化合物，更具体地，涉及3-N-取代-3-O-取代的红霉素A衍生物，它们是抗细菌药物，对革兰氏阳性或革兰氏阴性细菌和非典型病原体具有有效的作用。本发明的化合物对金黄色葡萄球菌、肺炎链球菌、肠球菌、大肠杆菌、铜绿假单胞菌、流感嗜血杆菌等尤其有效。本发明还涉及一种制备本发明化合物的方法，含有本发明化合物的制药组合物以及治疗细菌感染的方法。